Patents by Inventor Matthew Richard Reese
Matthew Richard Reese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230339930Abstract: The invention relates to compounds of Formula I wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: ApplicationFiled: July 7, 2021Publication date: October 26, 2023Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Qingyi Yang
-
Publication number: 20230167080Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, diabetes, kidney disease, NASH and heart failure.Type: ApplicationFiled: November 30, 2022Publication date: June 1, 2023Applicant: Pfizer Inc.Inventors: Leanne Marie BUZON, Kimberly O'Keefe CAMERON, Kevin Francis DEBOYACE, Kevin James FILIPSKI, David Andrew GRIFFITH, Bethany Lyn KORMOS, Shenping LIU, Luis Angel MARTINEZ ALSINA, Matthew Richard REESE, Rachel Jane ROTH FLACH, Yuan ZHANG
-
Publication number: 20230120254Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: September 14, 2022Publication date: April 20, 2023Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
-
Patent number: 11542270Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: GrantFiled: June 26, 2020Date of Patent: January 3, 2023Assignee: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Patent number: 11541034Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: GrantFiled: December 17, 2021Date of Patent: January 3, 2023Assignee: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Publication number: 20220363673Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: ApplicationFiled: June 24, 2020Publication date: November 17, 2022Applicant: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Christopher Ryan Butler, Kevin James Filipski, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Kiyoyuki Omoto, Brian Raymer, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Patent number: 11452711Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: GrantFiled: April 22, 2022Date of Patent: September 27, 2022Assignee: Pfizer Inc.Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
-
Publication number: 20220257563Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: April 22, 2022Publication date: August 18, 2022Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
-
Patent number: 11351149Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: GrantFiled: August 5, 2021Date of Patent: June 7, 2022Assignee: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Publication number: 20220142976Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: December 17, 2021Publication date: May 12, 2022Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Patent number: 11312713Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: March 6, 2018Date of Patent: April 26, 2022Assignee: Pfizer Inc.Inventors: Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Michael Chen, Jotham Wadsworth Coe, Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Christopher John Helal, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Luis Angel Martinez-Alsina, Martin Youngjin Pettersson, Matthew Richard Reese, Colin Richard Rose, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Joseph Scott Warmus, Yuan Zhang
-
Publication number: 20220062232Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.Type: ApplicationFiled: August 5, 2021Publication date: March 3, 2022Applicant: Pfizer Inc.Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
-
Publication number: 20210355117Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: ApplicationFiled: March 6, 2018Publication date: November 18, 2021Inventors: Michael Aaron BRODNEY, Thomas Allen CHAPPIE, Jinshan Michael CHEN, Jotham Wadsworth COE, Karen Jean COFFMAN, Paul GALATSIS, Michelle Renee GARNSEY, Christopher John HELAL, Jaclyn Louise Henderson, Bethany Lyn KORMOS, Ravi G. KURUMBAIL, Luis Angel MARTINEZ-ALSINA, Martin Youngjin PETTERSSON, Matthew Richard REESE, Colin Richard ROSE, Antonia Friederike STEPAN, Patrick Robert VERHOEST, Travis T. WAGER, Joseph Scott WARMUS, Yuan ZHANG
-
Patent number: 11059833Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: GrantFiled: October 23, 2020Date of Patent: July 13, 2021Assignee: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Publication number: 20210087204Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: ApplicationFiled: October 23, 2020Publication date: March 25, 2021Applicant: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Publication number: 20210024536Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.Type: ApplicationFiled: June 26, 2020Publication date: January 28, 2021Applicant: Pfizer Inc.Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
-
Patent number: 10039753Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: GrantFiled: September 12, 2016Date of Patent: August 7, 2018Assignee: Pfizer Inc.Inventors: Karen Jean Coffman, Paul Galatsis, Michelle Renee Garnsey, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Martin Youngjin Pettersson, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager
-
Publication number: 20170073343Abstract: The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.Type: ApplicationFiled: September 12, 2016Publication date: March 16, 2017Applicant: Pfizer Inc.Inventors: Paul Galatsis, Jaclyn Louise Henderson, Bethany Lyn Kormos, Ravi G. Kurumbail, Matthew Richard Reese, Antonia Friederike Stepan, Patrick Robert Verhoest, Travis T. Wager, Martin Youngjin Pettersson, Michelle Renee Garnsey